Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
NCT02811679Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in non-Hodgkin lymphoma (NHL), sponsored by Massachusetts General Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Aug 2016; status: terminated.
02
Drugs
blinatumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02811679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811679.